Search Results for "Sjogren A Belimumab"

02:51 EDT 30th May 2016 | BioPortfolio

Matching Channels


Matching News

Rheumatoid Factor Tied to Sjogren's Lymphoma (CME/CE)

(MedPage Today) -- Disease activity also contributed to blood cancer risk in Sjogren's syndrome


Class: Immunotherapy Generic Name: Belimumab Trade Name: Benlysta® For which conditions is this drug approved? Benlysta is approved to treat adults with active systemic lupus erythematosus (SLE or lu...

New study links cathepsin S protein to tear secretion in Sjogren's syndrome patients

The autoimmune disorder Sjogren's syndrome is often overlooked or misdiagnosed because the symptoms are similar to other conditions. Its characteristic symptoms are dry eyes and dry mouth, and reduced...

Regulatory update – BLA filed for Benlysta® (belimumab)

GlaxoSmithKline PLC (GSK) announced today that Human Genome Sciences, Inc. (HGS) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), for Benlysta (belim...

Regulatory update - Benlysta® (belimumab)

GlaxoSmithKline PLC (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA), for Benlysta (belimumab) for reducing disease activi...

GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis

GSK today announced the start of a Phase III study to evaluate Benlysta® (belimumab) in patients with ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis - a condition that involves inf...

Stratifying primary Sjögren’s syndrome: killers in the balance?

The article by Seror et al. in Arthritis Research & Therapy reports data from the 15 French patients in the open-label BELISS (Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Synd...

GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus

GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta (belimumab) as a potent...

Matching PubMed Articles

A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.

Belimumab is an approved therapy for the treatment of systemic lupus erythematosus (SLE). This study examined the real-world utilization patterns of belimumab and standard SLE therapies in patients af...

Belimumab in systemic lupus erythematosus: a perspective review.

Belimumab (Benlysta(®)) is a fully humanized monoclonal antibody that inhibits B-lymphocyte stimulator (also known as B cell activating factor of the tumor necrosis factor family) and was approved by...

Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.

Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody, appeared effective in Sjögren's syndrome (SS) in the phase II open-label 52-week BELISS study. Herein, the follow-up after the en...

Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.

The purpose of this analysis is to evaluate the cost-effectiveness of belimumab, a new biological treatment specifically developed for the treatment of Systemic Lupus Erythematosus (SLE), in the Itali...

Rituximab-refractory lupus nephritis successfully treated with belimumab.


Search Whole site using Google

Quick Search
Advertisement Advertisement